English

Choose language

Back

  • Deutsch

  • English

  • Español

  • Français

  • Polski

  • Русский

  • Українська


English

41% and 42% Profit Potential: Trade Two New IPO's!

In June alone, we invited you to trade seven IPO's, and all of them started trading as profitable! As such, Zoominfo stock went up by 90.48%, Vroom added 82.95%, while Legend Biotech price grew by 60.87%. Our congratulations to the investors!

Missed those IPO's? No worries, we have some great news. Freedom Finance analysts now recommend two more ambitious projects, which are Forma Therapeutics and Repare Therapeutics, two biotech companies with 42% and 41% potential, respectively. Hurry up, though: you can apply to trade both IPO's before today June 17, 19:00 (UTC+2).

Forma Therapeutics Holdings, Inc.

This company focuses on developing medical drugs for sickle cell disease and prostate cancer treatment at the clinical stage. Forma Therapeutics works with Bristol-Myers Squibb, which is one of the largest companies working on sickle cell disease treatment, and Boehringer Ingelheim.

In 2021, Forma Therapeutics is moving its clinical trials from phase 2 to phase 3, the company value growing with each phase. The products being developed are in-demand, as the number of cancer cases is rising. Thus, the company potential market amounts to $24B.

Key Facts:

● Earnings: 0

● Net Profit: -$8M

● Net Debt: 0

● Exchange: NASDAQ (trading as FMTX)

● IPO Size: 11.76M shares

● Starting Price: $16 to $18

● Profit potential: 42%

● Underwriters: Morgan Stanley, Goldman Sachs, Cowen, Piper Sandler


Trade FMTX IPO


Repare Therapeutics Inc.

This company is working on finding new ways of cancer treatment through synthetic lethality, which targets only cancer cells without affecting the healthy ones. The analysts say the first clinical trials phase (out of two) is to start in Q3 this year, while the sales will start in 2027. The potential target market amounts to $24B.

Key Facts:

● Earnings: 0

● Net Profit: -$13M

● Net Debt: 0

● Exchange: NASDAQ (trading as RPTX)

● IPO Size: 7.4M shares

● Starting Price: $16 to $18

● Profit potential: 41%

● Underwriters: Morgan Stanley, Goldman Sachs, Cowen, Piper Sandler


Trade RPTX IPO



How to Trade on an IPO

You can apply to trade both IPO's before June 17, 19:00 (UTC+2). In order to trade on an IPO, you need an investment account with Freedom Finance.

If you are already a Freedom Finance client, just log into your account to start trading.

If you don't have a Freedom Finance account yet, we recommend you opening it as soon as possible. Otherwise, you may miss it, as there are less than two days left before the IPO, while the account verification process after opening and funding it may take more than one business day.


*Investment in stocks and other financial instruments may result in loss of capital. Past investment results do not guarantee future returns. The forecasts are not reliable indicator of future performance.